Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 16,839 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication Clear all
Withdrawn Phase 4 Interventional

ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

NCT01926054
View directory record Official record
Conditions
SLE Glomerulonephritis Syndrome, WHO Class V
Interventions
Acthar gel
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Not applicable Interventional

The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma

NCT04760405
View directory record Official record
Conditions
Multiple Myeloma, Stem Cell Transplant Complications
Interventions
Tai Chi Easy
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Tucson, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression

NCT03228394
View directory record Official record
Conditions
Depression, Depressive Disorder, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorders, Puerperal Disorders, Pregnancy Complications, Postpartum, PPD
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Little Rock, Arkansas • Costa Mesa, California • Lemon Grove, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 2 Interventional

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

NCT00004066
View directory record Official record
Conditions
Ovarian Cancer, Sarcoma, Small Intestine Cancer
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin

NCT03211156
View directory record Official record
Conditions
Vaginitis Gardnerella
Interventions
Amoxicillin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 23, 2026, 12:53 AM EDT
Terminated Phase 2 Interventional

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

NCT00004856
View directory record Official record
Conditions
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
trastuzumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 23, 2026, 12:53 AM EDT
Completed No phase listed Observational

Risk of Chronic Kidney Disease Progression

NCT02654756
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 2 Interventional

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

NCT01044186
View directory record Official record
Conditions
Transfusional Iron Overload
Interventions
ICL670
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Oakland, California • Orange, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00011986
View directory record Official record
Conditions
Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Paclitaxel, Carboplatin, Gemcitabine Hydrochloride, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
4,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Not applicable Interventional Results available

Trial of Versajet Compared With Conventional Treatment in Acute and Chronic Wounds

NCT01050673
View directory record Official record
Conditions
Surgical Wound Dehiscence
Interventions
VERSAJET, Scalpel or blade
Device · Procedure
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 23, 2026, 12:53 AM EDT
Terminated No phase listed Observational

Vulvar Mucosal Specialty Clinic Chart Review

NCT02881229
View directory record Official record
Conditions
Vulvar Disease, Lichen Sclerosus, Lichen Planus, Vulvodynia
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 3 Interventional

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

NCT00171145
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Darifenacin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Timeline
2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced Oct 23, 2026, 12:53 AM EDT
Recruiting No phase listed Observational

Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies

NCT05213572
View directory record Official record
Conditions
Mortality in Sickle Cell, Sickle Cell Cardiopulmonary Complications, Sickle Cell Organ Damage, Sickle Cell Life Expectancy and Risk Factors for Early Death, Sickle Cell Lung Disease and Sudden Death
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Not applicable Interventional

Effectiveness of Kegel Exercise Device in Strengthening Pelvic Floor and Treating Urinary Incontinence (UI)

NCT02617472
View directory record Official record
Conditions
Stress Urinary Incontinence, Sexual Dysfunction
Interventions
Pelvic floor exerciser
Device
Lead sponsor
Lelo Inc.
Industry
Eligibility
20 Years to 69 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044395
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Mesa, Arizona • Irvine, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 23, 2026, 12:53 AM EDT
Terminated Phase 1 Interventional

Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer

NCT00158886
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Topotecan, Radiation therapy
Drug · Radiation
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 23, 2026, 12:53 AM EDT
Completed No phase listed Observational

Prevention of Amputation in Diabetic Foot Ulcers Using Amniotic Tissue

NCT02632929
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Not listed
Lead sponsor
Boise VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 1 Interventional

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

NCT01625351
View directory record Official record
Conditions
Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions
alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 23, 2026, 12:53 AM EDT
Not yet recruiting Phase 2 Interventional

Pressure Targeting During High Flow Therapy in Premature Infants

NCT07418502
View directory record Official record
Conditions
Preterm Infants, Respiratory Distress Syndrome (Neonatal), BPD - Bronchopulmonary Dysplasia
Interventions
Pressure Targeted High Flow, CPAP
Procedure
Lead sponsor
University of Texas at Austin
Other
Eligibility
7 Days to 40 Weeks
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
San Diego, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Not applicable Interventional

Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function

NCT01993732
View directory record Official record
Conditions
Cancer, Effects of Chemotherapy, Unspecified Complication of Bone Marrow Transplant, Auto Immune Disease
Interventions
Retrieval and Cryopreservation
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 2 Interventional Results available

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

NCT06011798
View directory record Official record
Conditions
Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
Interventions
Aflibercept, foselutoclax
Drug
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Not applicable Interventional

Ear Electro-stimulation for Chronic Pelvic Pain

NCT01345331
View directory record Official record
Conditions
Endometriosis
Interventions
Real stimulation VS Sham
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 23, 2026, 12:53 AM EDT
Completed No phase listed Observational

Environmental Factors in the Development of Polycystic Ovary Syndrome

NCT00341731
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Research Triangle Park, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 23, 2026, 12:53 AM EDT
Completed Phase 2 Interventional

Phase 2 Study in Patients With MiT Tumors

NCT00557609
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS)
Interventions
ARQ 197
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
13 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
San Francisco, California • Santa Monica, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 23, 2026, 12:53 AM EDT